Emergent BioSolutions (NYSE:EBS) Releases Quarterly Earnings Results, Beats Expectations By $4.24 EPS

Emergent BioSolutions (NYSE:EBS) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($3.65) by $4.24, Zacks reports. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 17.91%. The firm had revenue of $300.40 million during the quarter. During the same period in the prior year, the firm posted ($3.17) EPS. Emergent BioSolutions updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Emergent BioSolutions Stock Up 17.9 %

EBS stock traded up $0.59 during trading on Friday, hitting $3.89. 19,164,011 shares of the company’s stock traded hands, compared to its average volume of 4,497,321. The firm has a market capitalization of $203.80 million, a P/E ratio of -0.33 and a beta of 1.24. The business has a fifty day simple moving average of $2.46 and a two-hundred day simple moving average of $2.23. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $10.88.

Wall Street Analysts Forecast Growth

Separately, Benchmark reaffirmed a “buy” rating and set a $5.00 price target on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.